First International Symposium on Melanoma and Other Cutaneous Malignancies: 23-25 April 2004, New York, NY, USA

Expert Opinion on Biological Therapy

Volumn 4, Issue 9, 2004, Pages 1541-1546

  Tarhini, Ahmad A ^a   Agarwala, Sanjiv S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Dendritic cells; IFN; IL 2; Immunotherapy; Melanoma; Vaccines

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CANVAXIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DACARBAZINE; FLICE INHIBITORY PROTEIN; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN PEPTIDE COMPLEX 96; HIGH MOBILITY GROUP B1 PROTEIN; HISTAMINE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; MELACINE; MELAN A; MELANOMA VACCINE; NOTCH RECEPTOR; OBLIMERSEN; PACLITAXEL; PROTEIN KINASE INHIBITOR; SORAFENIB; TEMOZOLOMIDE; THALIDOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG MEGADOSE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MELANOMA; MELANOMA CELL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; VACCINATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHEMOPREVENTION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; LYMPH NODE EXCISION; LYMPHOMA, T-CELL, CUTANEOUS; MELANOMA; SALVAGE THERAPY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 4544350803     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.9.1541     Document Type: Conference Paper

References (22)

1. GERSHENWALD JE, THOMPSON W, MANSFIELD PF et al.: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J. Clin. Oncol. (1999) 17(3):976-983.
2. CASCINELLI N, MORABITO A, SANTINAMI M et al.: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet (1998) 351(9105):793-796.
3. BLEICHER R, ESSNER R, FOSHAG LJ et al.: Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J. Clin. Oncol. (2003) 21(7):1326-1331.
4. REEVES ME, DELGADO R, BUSAM KJ et al.: Prediction of nonsentinel lymph node status in melanoma. Ann. Surg. Oncol. (2003) 10(1):27-31.
5. KIRKWOOD JM, MANOLA J, IBRAHIM J et al.: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. (2004) 10(5):1670-1677. A valuable analysis of the evidence behind high-dose IFN-α therapy as the standard of care for high-risk (stages IIB and III) resected melanoma.
6. GRADILONE A, GAZZANIGA P, RIBUFFO D et al.: Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J. Clin. Oncol. (2003) 21(2):306-312.
7. FARMER PJ, GIDANIAN S, SHAHANDEH B et al.: Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res. (2003) 16(3):273-279.
8. SCAFFIDI P, MISTELI T, AND BIANCHI ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 418(6894):191-195.
9. POSER I, GOLOB M, BUETTNER R et al.: Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol. Cell. Biol. (2003) 23(8):2991-2998.
10. TAGUCHI A, BLOOD DC, DEL TORO G et al.: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 405(6784):354-360.
11. KUNIYASU H, CHIHARA Y, TAKAHASHI T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep. (2003) 10(2):445-448.
12. SHI Y, SAWADA J, SUI G et al.: Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature (2003) 422(6933):735-738.
13. BASTIAN BC, OLSHEN AB, LEBOIT PE et al.: Classifying melanocytic tumors based on DNA copy number changes. Am. J. Pathol. (2003) 163(5):1765-1770.
14. MALDONADO J, TIMMERMAN L, FRIDLYAND J et al.: Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am. J. Pathol. (2004) 164:1783-1787.
15. ESSNER R, KOJIMA M: Dendritic cell Function in sentinel nodes. Oncology (Hunting.) (2002) 16(1 Suppl. 1):27-31.
16. TERANDO A, ROESSLER B, MULÉ J: Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther. (2004) 11:165-173.
17. ASAVAROENGCHAI W, KOTERA Y, MULÉ J: Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. USA (2002) 99:932-938.
18. CHUNG M, GUPTA RK, HSUEH E et al.: Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J. Clin. Oncol. (2003) 21(2):313-319.
19. MIDDLETON MR, GROB JJ, AARONSON N et al.: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. (2000) 18(1):158-166.
20. O'DAY SJ, BOASBERG PD, PIRO L et al.: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin. Cancer Res. (2002) 8(9):2775-2781.
21. ATKINS MB, LOTZE MT, DUTCHER JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. (1999) 17(7):2105-2116. Data behind the FDA approval of high-dose IL-2 for metastatic melanoma.
22. AGARWALA SS, GLASPY J, O'DAY SJ et al.: Results from a randomized Phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J. Clin. Oncol. (2002) 20(1):125-133. Combination of histamine and low-dose IL-2 in a well-tolerated regimen revealing improved survival in patients with metastatic melanoma and liver metastases, not excluding patients with ocular primary.